Colon cancer cells treated with 5‑fluorouracil exhibit changes in polylactosamine‑type N‑glycans

Gao,Liping; Shen,Li; Yu,Meiyun; Ni,Jianlong; Dong,Xiaoxia; Zhou,Yinghui; Wu,Shiliang

doi:10.3892/mmr.2014.2008

Colon cancer cells treated with 5‑fluorouracil exhibit changes in polylactosamine‑type N‑glycans

Authors:
- Liping Gao
- Li Shen
- Meiyun Yu
- Jianlong Ni
- Xiaoxia Dong
- Yinghui Zhou
- Shiliang Wu
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Department of Clinical Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: March 5, 2014 https://doi.org/10.3892/mmr.2014.2008
Pages: 1697-1702

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5‑Fluorouracil (5‑FU) is the major chemotherapeutic agent for the treatment of colorectal carcinoma, which were found to have N‑glycans containing polylactosamine on the cancer cell surface. Alterations in the expression and structure of polylactosamine glycans are associated with cellular differentiation and oncogenesis. However, little is known with regard to the correlation between the levels of polylactosamine expressed in colon cancer cells and the anticancer effect of 5‑FU. In the present study, SW620 cells were treated with the half maximal inhibitory concentration (IC50; determined by MTT‑assay) of 5‑FU. Hoechst 33258 staining and flow cytometric analysis indicated that 5‑FU administration resulted in apoptosis in SW620 cells. An increased percentage of cells in S phase was also observed among the SW620 cells treated with 5‑FU. Under the same experimental conditions, a decrease in the 5‑FU‑induced inhibition of polylactosamine glycans was recorded. However, an increase in the activity of alkaline phosphatase was also observed. Furthermore, pretreatment of the SW620 cells with 5‑FU inhibited the expression of β1,3‑N‑acetylglucosaminyltransferase‑8 (β3Gn‑T8) and cluster of differentiation (CD)147 in a time‑dependent manner. Overall, changes in glycosylation were associated with the anticancer effect of 5‑FU in the colon cancer cells. In conclusion, polylactosamine may be a useful target for the identification of substances with anticancer activity.

View Figures

View References

1	Zhang DQ, Guo Q, Zhu JH and Chen WC: Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol. 11:162013. View Article : Google Scholar
2	Kalra AV and Campbell RB: Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 97:910–918. 2007. View Article : Google Scholar : PubMed/NCBI
3	De Graaf TW, Slot SS, Peters GJ and Van Dijk W: Changes in glycosylation of L1210 cells after exposure to various antimetabolites. Eur J Cancer. 29A:1760–1765. 1993.PubMed/NCBI
4	Yang JM, Byrd JC, Siddiki BB, et al: Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology. 4:873–884. 1994. View Article : Google Scholar : PubMed/NCBI
5	Barrow H, Tam B, Duckworth CA, Rhodes JM and Yu LG: Suppression of core 1 Gal-transferase is associated with reduction of TF and reciprocal increase of Tn, sialyl-Tn and Core 3 glycans in human colon cancer cells. PLoS One. 8:e597922013. View Article : Google Scholar : PubMed/NCBI
6	Balog CI, Stavenhagen K, Fung WL, et al: N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics. 11:571–585. 2012. View Article : Google Scholar : PubMed/NCBI
7	Hahne H, Neubert P, Kuhn K, et al: Carbonyl-reactive tandem mass tags for the proteome-wide quantification of N-linked glycans. Anal Chem. 84:3716–3724. 2012. View Article : Google Scholar : PubMed/NCBI
8	Togayachi A, Kozono Y, Ishida H, et al: Polylactosamine on glycoproteins influences basal levels of lymphocyte and macrophage activation. Proc Natl Acad Sci USA. 104:15829–15834. 2007. View Article : Google Scholar : PubMed/NCBI
9	Saitoh O, Wang WC, Lotan R and Fukuda M: Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 267:5700–5711. 1992.
10	Ishida H, Togayachi A, Sakai T, et al: A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett. 579:71–78. 2005. View Article : Google Scholar : PubMed/NCBI
11	Zhu S, Chu D, Zhang Y, et al: EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol. 30:3692013. View Article : Google Scholar : PubMed/NCBI
12	Jiang Z, Ge Y, Zhou J, Xu L and Wu SL: Subcellular localization and tumor distribution of human beta3-galactosyltransferase by beta3GalT7 antiserum. Hybridoma (Larchmt). 29:141–146. 2010. View Article : Google Scholar : PubMed/NCBI
13	Peng ZH, Xing TH, Qiu GQ and Tang HM: Relationship between Fas/FasL expression and apoptosis of colon adenocarcinoma cell lines. World J Gastroenterol. 7:88–92. 2001.PubMed/NCBI
14	Tong J, Xie G, He J, Li J, Pan F and Liang H: Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol. 2011:7405642011. View Article : Google Scholar : PubMed/NCBI
15	Remmers N, Anderson JM, Linde EM, et al: Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res. 19:1981–1993. 2013. View Article : Google Scholar : PubMed/NCBI
16	Mitsui Y, Yamada K, Hara S, Kinoshita M, Hayakawa T and Kakehi K: Comparative studies on glycoproteins expressing polylactosamine-type N-glycans in cancer cells. J Pharm Biomed Anal. 70:718–726. 2012. View Article : Google Scholar : PubMed/NCBI
17	Srinivasan N, Bane SM, Ahire SD, Ingle AD and Kalraiya RD: Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J. 26:445–456. 2009. View Article : Google Scholar
18	Nabi IR and Dennis JW: The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi residence time. Glycobiology. 8:947–953. 1998. View Article : Google Scholar : PubMed/NCBI
19	Seko A and Yamashita K: Activation of beta1,3-N-acetylglucosaminyltransferase-2 (beta3Gn-T2) by beta3Gn-T8. Possible involvement of beta3Gn-T8 in increasing poly-N-acetyllactosamine chains in differentiated HL-60 cells. J Biol Chem. 283:33094–33100. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lea MA, Ibeh C, Shah N and Moyer MP: Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. Anticancer Res. 27:741–748. 2007.PubMed/NCBI
21	Seko A and Yamashita K: Characterization of a novel galactose beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8): the complex formation of beta3Gn-T2 and beta3Gn-T8 enhances enzymatic activity. Glycobiology. 15:943–951. 2005. View Article : Google Scholar : PubMed/NCBI
22	Andreuccetti M, Allegrini G, Antonuzzo A, et al: Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. Eur J Cancer. 32A:1219–1226. 1996. View Article : Google Scholar : PubMed/NCBI
23	Steet RA, Melancon P and Kuchta RD: 3′-Azidothymidine potently inhibits the biosynthesis of highly branched N-linked oligosaccharides and poly-N-acetyllactosamine chains in cells. J Biol Chem. 275:26812–26820. 2000.
24	Tang W, Chang SB and Hemler ME: Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell. 15:4043–4050. 2004. View Article : Google Scholar : PubMed/NCBI
25	Dube DH and Bertozzi CR: Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov. 4:477–488. 2005. View Article : Google Scholar : PubMed/NCBI